Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus.
Kanerva A, Zinn KR, Chaudhuri TR, Lam JT, Suzuki K, Uil TG, Hakkarainen T, Bauerschmitz GJ, Wang M, Liu B, Cao Z, Alvarez RD, Curiel DT, Hemminki A.
Kanerva A, et al. Among authors: liu b.
Mol Ther. 2003 Sep;8(3):449-58. doi: 10.1016/s1525-0016(03)00200-4.
Mol Ther. 2003.
PMID: 12946318
Free article.